AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 8.7% according to Deutsche.
Deutsche set a target price of 13,000 GBX for the company, which when compared to the AstraZeneca plc share price of 11,956 GBX at opening today (09/05/2023) indicates a potential upside of 8.7%. Trading has ranged between 9,399 (52 week low) and 12,828 (52 week high) with an average of 1,444,201 shares exchanging hands daily. The market capitalisation at the time of writing is £182,039,340,000.
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
AstraZeneca plc 8.7% potential upside indicated by Deutsche
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials.
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care.
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer.
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
